Gilenya (fingolimod) is approved for multiple sclerosis. However, it is unclear of its
clinical effect in the Hispanics with MS given that clinical studies had limited
representation of this population. It is also unclear if Gilenya would be as effective in
individuals with disease predominantly affecting the optic nerve and spinal cord (OSMS)
commonly seen in Asian populations.
Objectives: To compare the clinical response of Gilenya® (fingolimod) in relapsing remitting
OSMS and MS of Hispanic descent using ancestral markers as a biomarker of treatment response
and clinical disease state.